These new findings are in line with our previous studies demonstrating that lymphatic transport of FITC Dextran in a murine model of NASH can be rescued with exogenous administration of VEGF-C after steatohepatitis has already been established (Burchill et al., 2021). This evidence concerns the gene VEGFC and metabolic dysfunction-associated steatohepatitis.